<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00861679</url>
  </required_header>
  <id_info>
    <org_study_id>ALL-SCT-BFM-0321-08-HMO-CTIL</org_study_id>
    <nct_id>NCT00861679</nct_id>
  </id_info>
  <brief_title>Therapy Protocol Acute Lymphoblastic Leukemia Stem Cell Transplantation International</brief_title>
  <acronym>ALL SCT BFM</acronym>
  <official_title>Therapy Protocol ALL SCT BFM International-open, Multicenter, Controlled, Prospective Study for Therapy and Therapy Optimisation in Patients With Acute Lymphoblastic Leukemia (ALL) and an Indication for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate whether HSCT from matched family or unrelated donors (MD) is equivalent to the&#xD;
      HSCT from matched sibling donors (MSD). To evaluate the efficacy of HSCT from mismatched&#xD;
      family or unrelated donors (MMD) as compared to HSCT from MSD/MD. To determine whether&#xD;
      therapy has been carried out according to the main HSCT protocol recommendations. The&#xD;
      standardisation of the treatment options during HSCT from different donor types aims at the&#xD;
      achievement of an optimal comparison of survival after HSCT with survival after chemotherapy&#xD;
      only. To prospectively evaluate and compare the incidence of acute and chronic GvHD after&#xD;
      HSCT from MSD, from MD and from MMD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>event-free and overall survival after allogeneic HSCT, occurrence of acute and chronic Graft-versus-Host-Disease (GvHD), occurrence and course of late effects after chemotherapy with subsequent allogeneic HSCT</measure>
    <time_frame>11 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">552</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>HSCT from matched family or unrelated donors(MD)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>HSCT from matched family or unrelated donors(MD) to matched related donors.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transplantation with Stem Cells from Umbilical Cord</intervention_name>
    <description>According to results from published experiences in children following suggestions are given:&#xD;
Number of Cells:&#xD;
Number of nucleated cells infused exceed 2,5x10*7/kg recipient BW or&#xD;
Number of nucleated cells collected exceed 3x10*7/kg BW&#xD;
Number of CD34+ cells infused exceed 2x10*5/kg Recipient BW&#xD;
GVHD-prophylaxis:&#xD;
• MSD: CSA 3 mg/kg as described in the protocol + Prednisolone 1 mg/kg (day O to day 15, then tapering until day 28)&#xD;
• UD: as above + additional immunosuppression according to local protocols; ATG might increase risk of infectious complication and might be replaced by other drugs according to local protocols.&#xD;
HLA-matching for unrelated CB: a matched UB is defined by 6/6 HLA matches (A, B antigenic medium resolution and DRB1 allelic) and allocate to the transplantation group &quot;MD&quot;. Less than 6/6 HLA matches allocate the patient to the &quot;MMD&quot; group.&#xD;
If many choices available ABO- major incompatibility should be avoided.</description>
    <arm_group_label>HSCT from matched family or unrelated donors(MD)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        all patients with ALL (except for patients with B-ALL) who fulfil the following criteria:&#xD;
&#xD;
          -  age at time of initial diagnosis or relapse diagnosis, respectively&#xD;
&#xD;
             ≤18 years&#xD;
&#xD;
          -  indication for allogeneic HSCT&#xD;
&#xD;
          -  complete remission (CR) is achieved before SCT&#xD;
&#xD;
          -  written consent of the parents (legal guardian) and, if indicated, the minor patient&#xD;
             via &quot;Informed Consent Form&quot;&#xD;
&#xD;
          -  no pregnancy&#xD;
&#xD;
          -  no secondary malignancy&#xD;
&#xD;
          -  no previous HSCT&#xD;
&#xD;
          -  HSCT is performed in a study participating centre.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  not signed inform consent of the parents (legal guardian)&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  secondary malignancy&#xD;
&#xD;
          -  previous HSCT&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Schneider Children's Medical Center of Israel</name>
      <address>
        <city>Petach Tikvah</city>
        <zip>49202</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <study_first_submitted>March 12, 2009</study_first_submitted>
  <study_first_submitted_qc>March 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2009</study_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HSCT</keyword>
  <keyword>ALL</keyword>
  <keyword>GvHD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

